![]() |
市場調查報告書
商品編碼
1474029
頭頸鱗狀細胞癌的細胞療法 - 研發管線分析:2024 年Cell Therapies in Head and Neck Squamous Cell Carcinoma - Pipeline Analytics 2024 |
過繼性細胞療法(ACT)在多種癌症的早期試驗中顯示出有希望的結果。然而,治療頭頸鱗狀細胞癌(HNSCC)的成功方法面臨實體瘤常見的獨特課題。這些課題包括需要為 T 細胞建立適當的歸巢機制,以有效地靶向腫瘤,確保腫瘤內有足夠的 T 細胞浸潤以產生強大的免疫反應,並且這包括識別不會對腫瘤產生影響的抗原。儘管 ACT 治療 HNSCC 仍處於起步階段,但人們樂觀地認為,它將在不久的將來在治療中發揮重要作用。這與檢查點抑制劑合併用於化療難治性患者和復發轉移的第一線治療具有潛力。
根據我們的分析,正在開發的細胞療法有多種可以幫助治療 HNSCC,包括 TCR T 細胞療法、腫瘤浸潤淋巴細胞 (TIL) 以及與免疫檢查點抑制劑 (ICIs) 的聯合療法。
本報告探討了頭頸鱗狀細胞癌的細胞療法,包括市場機會、關鍵競爭分析、公司管道藥物概況、臨床試驗和其他進展。
The Cell Therapies in Head and Neck Squamous Cell Carcinoma - Pipeline Analytics -2024 report published by Mellalta Meets covers the Cell Therapies market opportunity providing Key Competitive Analysis, 17+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports cover pipeline product analysis by stage of development, competitive landscape by phases, companies, clinical trials by regions, cell therapy modalities, and intervention type. Cell Therapies in Head and Neck Squamous Cell Carcinoma-Pipeline Analytics report adds value in terms of describing clinical-stage products for their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.
Adoptive cell therapies (ACT) have demonstrated promising outcomes in early-stage trials across various cancers. However, successful approaches in treating HNSCC face specific challenges commonly found in solid tumors. These challenges include the necessity to establish appropriate homing mechanisms for T cells to effectively target the tumor, ensuring adequate T-cell infiltration into the tumor for a robust immune response, and identifying antigens that will not lead to off-tumor effects. While ACT approaches are still in their early stages for HNSCC, there is optimism that they will soon play a significant role in treatment. This may involve potential combinations with checkpoint inhibitors for patients with chemotherapy-refractory disease and potentially in the first-line recurrent metastatic setting.
In this report, Mellalta Meets provides an in-depth analysis of the Cell Therapies in the HNSCC Pipeline covering preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy areas, investments, and acquisition trends. Currently, there are more than 17 candidates in the Cell Therapies in the HNSCC Pipeline under evaluation in clinical and preclinical studies. The major key players operating in the market are Iovance Biotherapeutics, ImmunityBio, Rapa Therapeutics, TCRCure Biopharma, Immatics, and many more which have a robust clinical pipeline of cell therapy candidates for HNSCC.
As per analysis, the development pipeline is full of different cell therapy modalities like TCR T-cell therapies, tumor-infiltrating lymphocytes (TILs), and combination approaches with immune checkpoint inhibitors (ICI) which can help in addressing HNSCC.
Mellalta's HER2-Low Breast Cancer Pipeline Report - Key Highlights
There are 5 products in the Phase 2 and Phase 1/2 stage of development, representing 15% of the total share of the developing Cell Therapies in HNSCC.
The HNSCC cell therapies landscape is dominated by Phase 1 stage assets accounting for 54.55% followed by Discovery stage products which account for 24.24%.
To be continued...
Report Coverage:
Indication Prioritization: HNSCC market potential
Business Transactions & Strategies: Key collaborations and deal values
HNSCC Cell Therapies Pipeline Development: Product Profiles, Clinical Trials & Results
HNSCC Cell Therapies Acquisition Targets
HNSCC Cell Therapies Competitive Intelligence
Recent and upcoming events